Search results for "disease-specific survival"

showing 1 items of 1 documents

Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis

2020

There is scant evidence about optimal management of poorly differentiated neuroendocrine carcinoma of the bladder (BNEC). We performed a multicenter retrospective study on BNEC patients from 13 Italian neuroendocrine-dedicated centers to analyze strategies associated with better outcomes. Mixed adeno-neuroendocrine carcinomas (MANEC) were included. We analyzed overall survival (OS) in the overall cohort, relapse-free survival (RFS) in radically operated patients and progression-free survival (PFS) in patients who received chemotherapy for metastatic disease. Fifty-one BNEC patients were included (male: 46, median age: 70 years). Overall, median OS was 16.0 months, radical tumor resection wa…

Oncologymedicine.medical_specialtymedicine.medical_treatmentNeuroendocrine Carcinoma (NEC)030232 urology & nephrologylcsh:MedicineDiseaseSmall-cell carcinomaArticle03 medical and health sciences0302 clinical medicineInternal medicineMedicinedisease-specific survivalStage (cooking)prognostic factorbladdersmall cell carcinomaChemotherapyPerformance statusbusiness.industryPoorly differentiatedlcsh:Rprognostic factorsRetrospective cohort studyGeneral Medicinemedicine.diseaseperioperative chemotherapy030220 oncology & carcinogenesisCohortbusinessbladder; disease-specific survival; neuroendocrine carcinoma (nec); perioperative chemotherapy; prognostic factors; small cell carcinomaJournal of Clinical Medicine
researchProduct